ライフサイエンスコーパス: blood glucose level

1 tures enabling potential seamless control of blood glucose level.

2 ly dependent on dietary condition but not on blood glucose level.

3 y state, and K(i) did not correlate with the blood glucose level.

4 tics with hospital mortality, independent of blood glucose level.

5 e associated with mortality, irrespective of blood glucose level.

6 sal of diabetes was determined by monitoring blood glucose level.

7 ase and G6Pase mRNA abundance and raised the blood glucose level.

8 ny actions that can raise or reduce falls in blood glucose level.

9 ociation being altered depending on maternal blood glucose level.

10 MN patches, leading to a gradual decrease in blood glucose levels.

11 corticoid receptor blockade lowered elevated blood glucose levels.

12 ic hypoglycemia and increased variability of blood glucose levels.

13 of the incretin peptide hormones regulating blood glucose levels.

14 x proteins, and albuminuria without changing blood glucose levels.

15 in levels in fasted mice, as well as fasting blood glucose levels.

16 significant dose-dependent reductions in fed blood glucose levels.

17 d tacrolimus/sirolimus also increased random blood glucose levels.

18 6 h but fell thereafter, concomitantly with blood glucose levels.

19 g a sigmoidal kinetic response to increasing blood glucose levels.

20 to the mechanism by which RTEF-1 attenuates blood glucose levels.

21 ne of several peptide hormones that increase blood glucose levels.

22 ating insulin release and maintaining normal blood glucose levels.

23 of hypoglycemia, SSTR2a did not alter basal blood glucose levels.

24 abetes was determined by daily monitoring of blood glucose levels.

25 omoted gluconeogenesis and increased fasting blood glucose levels.

26 and obese mice resulted in decreased fasting blood glucose levels.

27 ose tolerance, and significantly reduces the blood glucose levels.

28 eased hepatic glucose production and reduced blood glucose levels.

29 cular cells that directly encounter elevated blood glucose levels.

30 try, circulating human C-peptide levels, and blood glucose levels.

31 n, perturbed energy metabolism, and elevated blood glucose levels.

32 homeostasis of hepatic glycogen storage and blood glucose levels.

33 rect, simple and less invasive monitoring of blood glucose levels.

34 involves the release of hormones to restore blood glucose levels.

35 r example, blood permittivity depends on the blood glucose levels.

36 erated the liver injury and normalization of blood glucose levels.

37 flozin, increase glucose excretion and lower blood glucose levels.

38 lipotoxicity and is associated with improved blood glucose levels.

39 ocin [HFD/STZ]) to induce a mild increase in blood glucose levels.

40 action was observed without any reduction in blood glucose levels.

41 versed diastolic dysfunction, and normalized blood glucose levels.

42 GSK2141795 did not significantly influence blood glucose levels.

43 play important, opposing roles in regulating blood glucose levels.

44 Diabetic animals showed significantly higher blood glucose levels (10.8 +/- 0.7 vs. 8.4 +/- 0.5 mmol/

45 age, both GK and WKY cohorts showed similar blood glucose levels (112+/-14 mg/dL) and similar rates

46 dysfunction (E/E' 14 +/- 1), and normalized blood glucose levels (7.5 +/- 0.7 mmol/L).

47 nsive insulin therapy (IIT) targeting normal blood glucose levels (81-108 mg/dl) increases the incide

48 resulted in significantly increased fasting blood glucose levels, a blunted insulin response with de

49 onatal hyperglycemia (defined as pre-feeding blood glucose levels above 200mg/dl on two consecutive m

50 red GcgR monoclonal antibody displayed lower blood glucose levels accompanied by elevated plasma ghre

51 HT decreased blood glucose levels, adipocyte size, and triglyceride a

52 Circulating blood glucose levels affect ChREBP activity in hepatocyt

53 Pigs receiving IDN6556 had lower fasting blood glucose level after transplantation and a higher p

54 mportantly, NT-ES-beta-cells maintain normal blood glucose levels after ablation of the mouse endogen

55 High admission blood glucose levels after acute myocardial infarction a

56 for dietary intake, body weight, and fasting blood glucose levels after islet transplantation.

57 ation with glucose dehydrogenase to regulate blood glucose level, alcohol dissolution into carboxylic

58 A lowered blood glucose level also was observed in overnight-faste

59 gliptin, an antidiabetic agent, which lowers blood glucose levels, also reduces postprandial lipid ex

60 tide that plays an important role regulating blood glucose levels, analogues of which are used for tr

61 fluid glucose level is representative of the blood glucose level and follows it without significant d

62 Routine measurements of blood glucose level and glycohemoglobin level were perfo

63 a variable rate via a leg vein to double the blood glucose level and hepatic glucose load throughout

64 -)) display resistance to T1D as the rise in blood glucose level and islet inflammation were signific

65 s to assess the association between elevated blood glucose level and mortality in acute heart failure

66 that anti-CD44 antibody treatment decreases blood glucose levels and adipose tissue macrophage accum

67 ectly hyperactivate GK (GK activators) lower blood glucose levels and are being evaluated clinically

68 ic mice resulted in a sustained reduction in blood glucose levels and body weight gains up to 5-7 day

69 he success of GLP-1-based agents in lowering blood glucose levels and BW, we hypothesized that an ind

70 study is to assess the relationship between blood glucose levels and clinical parameters of periodon

71 ing increased body weight, visceral fat, and blood glucose levels and decreased leptin sensitivity.

72 s and benefits, the significance of abnormal blood glucose levels and diabetes as cardiovascular risk

73 Blood glucose levels and disease severities were analyze

74 Allograft survival was determined by fasting blood glucose levels and flow cytometric techniques were

75 oral administration of ANC improved fasting blood glucose levels and glucose tolerance in hyperglyca

76 lockade in the NAc bidirectionally modulated blood glucose levels and glucose tolerance.

77 gs demonstrate good correlation of reference blood glucose levels and glucose values obtained with th

78 Insulin treatment reduced blood glucose levels and heart defects.

79 eatment with a carbohydrate-rich diet raised blood glucose levels and improved retinal function in Gc

80 nally, we show that 13d significantly lowers blood glucose levels and increases concomitant beta-cell

81 F-1(-/-) mice showed significantly increased blood glucose levels and insulin resistance, accompanied

82 Recipient mice were monitored for blood glucose levels and measured for insulin-secretion

83 eatment for type 2 diabetes by reducing both blood glucose levels and platelet aggregation.

84 n ventilation and CO2 sensitivity to restore blood glucose levels and prevent a fall in blood pH.

85 1 and advanced type 2 diabetics to maintain blood glucose levels and prolong lives.

86 e that exogenous apoA-IV injection decreases blood glucose levels and stimulates a transient increase

87 he vasculature that affect the regulation of blood glucose levels and the development of atherosclero

88 ccordingly, the Rosa-Lkb1 mice had increased blood glucose levels and were intolerant to glucose chal

89 ptide-1 (GLP-1) has the ability to lower the blood glucose level, and its regulatory functions make i

90 e demographic data, blood pressures, fasting blood glucose level, and lipid profile.

91 ed acoustic startle response, US expectancy, blood glucose levels, and arousal ratings.

92 UACR and 8-OHdG, low-density lipoprotein and blood glucose levels, and duration of diabetes in patien

93 Abnormal blood pressure, blood glucose levels, and fever in the setting of arteri

94 er augments gluconeogenesis, raising fasting blood glucose levels, and hepatic FoxO6 depletion suppre

95 out (HKO) mice exhibited normal body weight, blood glucose levels, and insulin sensitivity.

96 Abnormalities of blood pressure, blood glucose levels, and temperature are prevalent in c

97 e best medical management of blood pressure, blood glucose levels, and temperature in pediatric patie

98 secreting alpha cells maintain physiological blood glucose levels, and their malfunction drives diabe

99 ogether hormonal control of blood volume and blood glucose levels, and thus adding to our understandi

100 The risk associated with an elevated blood glucose level appeared consistent across all subgr

101 mmencing insulin dosing when two consecutive blood glucose levels are > 180 mg/dL, targeting an upper

102 e indicates that pre-diagnostic diabetes and blood glucose levels are inversely related to glioma ris

103 slet activity persist, and relatively normal blood glucose levels are maintained.

104 l function; therefore, therapies that reduce blood glucose levels are of great interest in not only c

105 Blood glucose levels are tightly controlled by the coord

106 h of gray and white matter in children whose blood glucose levels are well within the current treatme

107 several studies implicate small declines in blood glucose levels as stimulus for spontaneous meal in

108 icantly increased plasma insulin and reduced blood glucose levels, as compared to control littermates

109 y 98.3% degree of gelatinization and maximal blood glucose level at 30min).

110 ization ( approximately 53.8%) and a maximal blood glucose level at 60min (slower glycemic response)

111 The individual's blood glucose level at the time of obtaining saliva was

112 population with diabetes, the change in the blood glucose level at the time of scan across longitudi

113 Higher blood glucose levels at admission and during the first 3

114 icantly heavier and had significantly higher blood glucose levels at the time of delivery than offspr

115 sting, LGSKO mice reach within 4 h decreased blood glucose levels attained by control floxed mice onl

116 effectively counterbalance a decline of the blood glucose level becomes even more pronounced in case

117 patients then underwent treatment to control blood glucose levels before end blood samples were taken

118 r rates of severe hypoglycemia, defined as a blood glucose level below 40 mg per deciliter (2.2 mmol

119 are equipped with alpha-cells increasing the blood glucose level, beta-cells decreasing it, and delta

120 Intensive insulin therapy maintained blood glucose levels between 80 and 110 mg/dL.

121 Blood glucose level (BGL), National Institute of Health

122 CREBH deficiency leads to reduced blood glucose levels but increases hepatic glycogen leve

123 urrent drugs for type 2 diabetes (T2D) lower blood glucose levels but they do not directly alleviate

124 Cerebral K(i) varies inversely with blood glucose level, but the measured cerebral MRGlu doe

125 to participate significantly in maintaining blood glucose levels, but their contribution to endogeno

126 GLP-1 is capable of regulating the blood glucose level by insulin secretion after administr

127 Pancreatic islets manage elevations in blood glucose level by secreting insulin into the bloods

128 pound 9m at 3, and 10 mpk po in feed lowered blood glucose levels by 89% and 94% at day 10, respectiv

129 Metformin lowers blood glucose levels by inhibiting hepatic glucose produ

130 ng a basal clamp, we found that BDNF lowered blood glucose levels by potently suppressing HGP, withou

131 glucose homeostasis in vivo Nrf2 suppresses blood glucose levels by protecting pancreatic beta cells

132 ess, feeding and reward-seeking, and control blood glucose levels by regulating sympathetic outflow t

133 Modulation of blood glucose levels by suppressing insulin release was

134 rodents, acute brain insulin action reduces blood glucose levels by suppressing the expression of en

135 , the GK rats showed significantly increased blood glucose levels (by 92+/-12%; p<0.05) and higher nu

136 hat for a person with type II diabetes, both blood glucose levels can be controlled and healthy oscil

137 an impact of a given meal on an individual's blood glucose levels can serve as the engine for a new g

138 functional islet mass, such as BLI (but not blood glucose levels), can prompt the appropriate timing

139 report, we make the unexpected finding that blood glucose levels change significantly during the cou

140 Blood glucose levels changed in accordance with how much

141 hibited reciprocal phenotypes as well as low blood glucose levels compared with wild type littermates

142 Only 8% monitored their blood glucose levels daily, 15% monitored weekly, and 10

143 Blood glucose levels declined by 11% beginning approxima

144 ot fibroblast cells significantly controlled blood glucose levels, delayed diabetes onset, ameliorate

145 on to diabetes in patients who have abnormal blood glucose levels detected by screening.

146 BALB/c mice showed a significant increase in blood glucose levels, developed polyuria, and succumbed

147 Sulphonylurea therapy rapidly normalizes blood glucose levels, dissipates glycogen stores, increa

148 Hepatic glucose production (HGP) maintains blood glucose levels during fasting but can also exacerb

149 S) in isolated islets, as well as effects on blood glucose levels during intraperitoneal glucose tole

150 ogenesis is important for maintaining steady blood glucose levels during starvation and through light

151 d progress to permanently extremely elevated blood glucose levels, early tight control of blood gluco

152 or null mice and also helps maintain fasting blood glucose levels, ensuring an adequate supply of nut

153 e hyperglycemia was defined as 2 consecutive blood glucose levels exceeding 216 mg/dL at least 3 hour

154 Hemoglobin A1c (HbA1c) and fasting blood glucose levels (FBGLs) were recorded.

155 [PD], marginal bone loss [MBL]) and fasting blood glucose levels (FBGLs) were recorded.

156 In addition, fasting blood glucose levels for DKO mice were significantly low

157 oximately four days and sustained control of blood glucose levels for more than a week in mice.

158 icant correlation was found between tear and blood glucose levels for multiple rabbits, suggesting th

159 successfully normalized and maintained host blood glucose levels for over 370 days in the absence of

160 failure, muscle weakness, and hyperglycemia (blood glucose level >150 mg/dL [to convert to millimoles

161 s, tight glycemic control targeting a normal blood glucose level has not been shown to improve outcom

162 radation of the incretins and the control of blood glucose levels have been demonstrated in biologica

163 tes duration, being under insulin treatment, blood glucose level, having non-communicable diseases we

164 Lower fasting blood glucose levels, higher insulin, and lower islet am

165 bumin excretion, glomerular hyperfiltration, blood glucose levels, histological deterioration and sys

166 erval (CI): 1.06, 1.52), an elevated fasting blood glucose level (HR = 1.20, 95% CI: 1.03, 1.39), and

167 2) has emerged as a promising way to control blood glucose level in diabetes patients.

168 There was a reduction in fat mass and blood glucose level in infected db/db mice.

169 ates whether perceived time has an effect on blood glucose level in people with type 2 diabetes.

170 Finally, the low basal blood glucose level in the HHS mouse model is improved u

171 d hemoglobin (HbA1c), reflecting the average blood glucose level in the proceeding 2-3 months, is rec

172 ialysis - as a means to dynamically modulate blood glucose levels in awake, freely moving mice while

173 Leptin treatment normalized blood glucose levels in both groups.

174 A rapid decrease occurred in blood glucose levels in both models, and all animals rea

175 tively enhanced GK translocation and reduced blood glucose levels in diabetic animals.

176 Blood glucose levels in diabetic mice were decreased dra

177 after short-term transplantation, and reduce blood glucose levels in diabetic mice.

178 lly actuated to deliver Metformin and reduce blood glucose levels in diabetic mice.

179 e appeared as viable therapeutics to control blood glucose levels in diabetic patents.

180 active form with corresponding reduction in blood glucose levels in diabetic rats.

181 was determined by its ability to reduce the blood glucose levels in diabetic rats.

182 ) were effective in acutely lowering fasting blood glucose levels in diet induced obese hyperglycemic

183 ry rat hepatocytes and significantly lowered blood glucose levels in fasted rats.

184 t sufficient over the short term to maintain blood glucose levels in fasted, fat-depleted mice.

185 cant amounts of glucose in order to maintain blood glucose levels in healthy subjects.

186 Statin therapy is known to increase blood glucose levels in humans.

187 cagon-like peptide-1 PODs was able to reduce blood glucose levels in mice for up to 5 d, 120 times lo

188 n of depot forming GLP-1-ELP fusions reduced blood glucose levels in mice for up to 5 days, 120 times

189 iac malformations, we observed that maternal blood glucose levels in models including insulin were st

190 sEPD of insulin was found to maintain blood glucose levels in normal range for at least 6h in

191 le subcutaneous injection failed to maintain blood glucose levels in normal range.

192 s also evident from markedly reduced fasting blood glucose levels in ob/ob-klotho DKO mice, compared

193 ure D3S5G dose-dependently decreased fasting blood glucose levels in obese C57BL/6J mice, and decreas

194 ance tests demonstrated significantly higher blood glucose levels in PANDER(-/-) versus wild-type mal

195 lights the importance of close monitoring of blood glucose levels in patients taking rapamycin as an

196 tors (AMG-1694 and AMG-3969) that normalized blood glucose levels in several rodent models of diabete

197 nd on transplantation were able to normalize blood glucose levels in streptozotocin diabetic NOD/SCID

198 at facilitates enzyme-mediated regulation of blood glucose levels in the body.

199 Blood glucose levels in the diabetic mice transplanted w

200 eleted p300 mice exhibited significant lower blood glucose levels in the fasted and post-prandial sta

201 Blood glucose levels in the glucagon-like peptide-1 grou

202 ing induction of NIDDM significantly lowered blood glucose levels in the majority of animals, which w

203 The liver responds to an increase in blood glucose levels in the postprandial state by uptake

204 n directly into the VMN also lowered fasting blood glucose levels in uncontrolled insulin-deficient d

205 sponse of the nanosensors tracked changes in blood glucose levels in vivo that were comparable to mea

206 ceived ALS after transplant when prompted by blood glucose levels increasing approximately 20% from t

207 Outside of its effects on blood glucose levels, insulin resistance is also associa

208 ghrelin receptor antagonist further reduced blood glucose levels into the markedly hypoglycemic rang

209 ebral K(i) was inversely related to elevated blood glucose levels, irrespective of administration rou

210 however, unsettled as to whether an elevated blood glucose level is the cause or consequence of incre

211 r percentage (100% vs. 33.3%) showed fasting blood glucose levels less than 11 mM.

212 Controlling blood glucose levels < or =120 mg/dL using an intensive

213 They displayed higher blood glucose levels, marked hypoinsulinemia, and reduce

214 or the development of biosensing systems for blood glucose level monitoring will be discussed, in vie

215 al lipidome between participants with normal blood glucose levels (n = 26) and those with type 2 diab

216 aumatic brain injury (TBI), although optimal blood glucose levels needed to maximize outcomes for the

217 were preceded by 5 min dips in VMH (but not blood) glucose levels, neither blood nor VMH levels decl

218 I, -2.9% to -1.4%]) (24 studies) and fasting blood glucose level (net change, -0.12 mmol/L [-2.2 mg/d

219 t Fxyd2(-/-) mice showed significantly lower blood glucose levels, no signs of peripheral insulin res

220 ed food intake and body weight and increased blood glucose levels; no change in HR or activity was ob

221 ed countries, including lower risk of raised blood glucose levels, obesity, tobacco, and aging, where

222 in to mimic the changes in serum insulin and blood glucose levels observed after intranasal insulin.

223 In contrast, the lowered fasting blood glucose levels observed in ghrelin receptor-defici

224 eive insulin glargine (with a target fasting blood glucose level of </=95 mg per deciliter [5.3 mmol

225 Hyperglycemia was defined as a blood glucose level of 200 mg/dL or greater.

226 controlled diabetes mellitus, with a fasting blood glucose level of 410 mg/dL (22.8 mmol/L) and a hem

227 The rate of documented hypoglycemia with a blood glucose level of 55 mg per deciliter (3.1 mmol per

228 RECOMMENDATION 3: ACP recommends a target blood glucose level of 7.8 to 11.1 mmol/L (140 to 200 mg

229 e of an insulin-dosing algorithm targeting a blood glucose level of 80 to 110 mg per deciliter [4.4 t

230 it from tight glycemic control targeted to a blood glucose level of 80 to 110 mg per deciliter, as co

231 8) We suggest that clinicians target a blood glucose level of less than 180 mg/dL in patients r

232 eatment for glucose control, or had a random blood glucose level of more than 200 mg/dl.

233 ibed on page 3115, effectively regulates the blood glucose level of type-1 diabetic mice, achieving a

234 stant nutrition and controlled exercise, the blood glucose levels of a person with type I diabetes ca

235 Our results show that HNP-1 reduced blood glucose levels of both normal mice and Zucker diab

236 Relative to maternal blood glucose levels of infants without cardiac malforma

237 The effects of dietary condition and blood glucose level on the kinetics and uptake of (18)F-

238 hough physiologic leptin replacement lowered blood glucose levels only slightly, it fully normalized

239 The NF-kappaB inhibition did not affect blood glucose level or body weight.

240 sured cerebral MRGlu does not correlate with blood glucose level or dietary condition.

241 ot have hypertension, dyslipidemia, abnormal blood glucose levels, or diabetes to behavioral counseli

242 actors (hypertension, dyslipidemia, abnormal blood glucose levels, or diabetes).

243 alysis, corrected for baseline risk factors, blood glucose levels outside the normoglycemic range, hi

244 MG were significantly associated with higher blood glucose levels (P = 3.9E(-4)).

245 It is known that even normal blood glucose levels physiologically inhibit glycogen ph

246 are essential for the maintenance of animal blood glucose levels, plant nectar production, and plant

247 own that resveratrol supplementation reduces blood glucose levels, preserves beta-cells in islets of

248 expression of ATP-insensitive KATP channels, blood glucose levels rapidly rose to >500 mg/dL.

249 ults suggest a mechanism whereby oscillatory blood glucose levels recruit non-oscillating islets to e

250 ecipients were followed for stabilization of blood glucose levels, reduction of exogenous insulin req

251 as evident in diabetes patients with similar blood glucose levels regardless of which glycated hemogl

252 nt reactive oxygen species production, while blood glucose levels remained unchanged.

253 when glucose uptake is compromised, raising blood glucose levels restores collagen synthesis in Runx

254 When blood glucose levels return to normoglycemia beta-cell m

255 ction was monitored by measurement of random blood glucose levels, serum glycosylated hemoglobin (HbA

256 rs, obtaining a close correlation with their blood glucose levels, simplifying and reducing the costs

257 tudies to determine whether tear glucose and blood glucose levels sufficiently correlate for applicat

258 ly, we found that brain endozepines modulate blood glucose levels, suggesting their involvement in a

259 ived time will have a greater influence over blood glucose level than actual time.

260 with Glu-OC experienced significantly lower blood glucose levels than Glu-OCN-treated wild-type mice

261 /-):Ins2(+/Akita) mice showed a reduction in blood glucose levels that correlated with the ameliorati

262 he lumen of rat jejunum caused a decrease in blood glucose levels that was PIP peptide and insulin do

263 , consisting of duration of obesity, fasting blood glucose levels, the presence of high blood pressur

264 c potency in the suppression of postprandial blood glucose levels thereby possibly preventing diabete

265 of Langerhans are the regulators of in vivo blood glucose levels through the secretion of endocrine

266 in resistance, as revealed by the failure of blood glucose levels to decrease after insulin injection

267 Blood glucose level, total leukocyte count, neutrophil c

268 ed mice exhibited reductions in body weight, blood glucose levels, total cholesterol (TC), leptin, to

269 the Ay-yellow obese gene (KKAy) mice lowered blood glucose levels toward the normoglycemic range.

270 The authors demonstrate that high blood glucose levels trigger neutrophil release of S100

271 macodynamic effect and significantly reduced blood glucose levels up to 6 h postdose.

272 ce, both compounds significantly lowered fed blood glucose levels (up to 58%).

273 glucoregulatory system (BCGS) that can lower blood glucose levels via both insulin-dependent and -ind

274 In the fully adjusted model, an elevated blood glucose level was an independent predictor of 30-d

275 patient with normal fasting ( = pre-feeding) blood glucose levels was matched in terms of gestational

276 Coincident with the induced elevations in blood glucose levels, we documented alternative pathway

277 ional insulin therapy (infusing insulin when blood glucose levels were >12 mmol/L and stopping at 10

278 Mean fasting blood glucose levels were equivalent between groups at a

279 As expected, pre-diagnostic blood glucose levels were inversely related to glioma ri

280 tes soon after birth, and by 5 weeks of age, blood glucose levels were markedly increased and insulin

281 Blood glucose levels were measured before and after the

282 Food intake, body weight, and blood glucose levels were measured daily, with body comp

283 Changes in blood glucose levels were measured in 46 participants wi

284 Fasting blood glucose levels were measured using a glucometer.

285 dical database, nutritional information, and blood glucose levels were merged for analysis.

286 Body weights, blood glucose levels were monitored throughout the study

287 Blood glucose levels were nearly identical in both group

288 blood vessel ablation, basal and stimulated blood glucose levels were only slightly increased, while

289 which plasma insulin levels were identical, blood glucose levels were reduced in G6pc2 KO mice, agai

290 In Keap1MuKO mice, blood glucose levels were significantly downregulated an

291 Mean fasting blood glucose levels were significantly higher in dogs w

292 Under HFD conditions, blood glucose levels were significantly lower (by >30%)

293 After cessation of sub-acute dosing, fasting blood glucose levels were significantly lower in ZDF rat

294 Within 17 weeks blood glucose levels were stabilized in animals injected

295 ARA 290 treatment significantly improved the blood glucose levels when compared to those of control a

296 lone elicited a rapid decline in circulating blood glucose levels, which appeared to induce endogenou

297 ith increasing blood glucose, correction for blood glucose level will make SUV a more robust outcome

298 Normalization of blood glucose levels with GCGR-blocking antibody unexpec

299 xploit a new cellular mechanism for lowering blood glucose levels with reduced potential for hypoglyc

300 r disease was associated with improvement in blood glucose levels, with evidence of altered expressio